Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GLK-221 Ophthalmic Solution
GLK-221 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GLK-221 Ophthalmic Solution | EXPERIMENTAL | GLK-221 Ophthalmic Solution administered topically twice daily to both eyes |
| Placebo | PLACEBO_COMPARATOR | Placebo Ophthalmic Solution administered topically twice daily to both eyes |
| Name | Type | Description |
|---|---|---|
| GLK-221 Ophthalmic Solution | DRUG | GLK-221 Ophthalmic Solution administered twice daily to both eyes |
| Placebo Ophthalmic Solution | DRUG | Placebo Ophthalmic Solution administered twice daily to both eyes |
Inclusion Criteria: * Be ≥ 18 and ≤ 55 years of age * Diagnosis of keratoconus in the study eye Exclusion Criteria: * Pregnant, lactating or planning a pregnancy * Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
GLK-221 is an investigational ophthalmic solution being developed for the treatment of keratoconus, a progressive eye condition that thins and bulges the cornea. It is a small molecule therapy administered as eye drops. GLK-221 is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
GLK-221 is being developed by Glaukos Corporation, a company traded on the New York Stock Exchange under the ticker symbol GKOS. Glaukos is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of GLK-221 ophthalmic solution in patients with keratoconus.
GLK-221 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is actively recruiting participants in the United States to assess the safety and efficacy of GLK-221 for keratoconus.
GLK-221 is being studied in a Phase 2 clinical trial registered as NCT07400952. This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of GLK-221 ophthalmic solution in subjects with keratoconus. The trial plans to enroll 100 participants aged 18 years and older in the United States.
Yes, GLK-221 and GLK-221 Ophthalmic Solution refer to the same investigational drug. The ophthalmic solution is the formulation being tested in clinical trials for keratoconus. The drug is administered as eye drops and is currently in Phase 2 development by Glaukos Corporation.